• Coronado Biosciences Inc., of Burlington, Mass., closed a $15 million secured loan facility with Hercules Technology Growth Capital Inc. Proceeds will support Coronado's clinical programs for Trichuris suis ova (CNDO-201), a biologic therapy for autoimmune disease, and CNDO-109, a biologic therapy for acute myeloid leukemia and solid tumors.
